HAIR Restoration Robotics Inc

Restoration Robotics® Announces Preliminary Unaudited Fourth Quarter 2018 Revenue

Restoration Robotics® Announces Preliminary Unaudited Fourth Quarter 2018 Revenue

Sold 17 ARTAS® Systems; Anticipates Net Revenue of $6.4 to $6.7 Million

SAN JOSE, Calif., Jan. 07, 2019 (GLOBE NEWSWIRE) -- Restoration Robotics, Inc. (NASDAQ:HAIR), a global leader in robotic hair restoration, announced today preliminary unaudited revenue for the fourth quarter ended December 31, 2018.

Preliminary unaudited consolidated net revenue in the fourth quarter of 2018 is expected to be in the range of $6.4 to $6.7 million, compared to $5.9 million in the fourth quarter of 2017, driven by the sale of 17 ARTAS® Systems, 11 of which were sold in the U.S.

Ryan Rhodes, President and Chief Executive Officer of Restoration Robotics, stated, “I am very pleased with our fourth quarter performance and our ability to accelerate commercial momentum both domestically and abroad. During the quarter we sold 11 ARTAS iX™ systems in the U.S, the highest number of systems sold domestically in company history.  Additionally, we shipped two ARTAS iX Systems to customers in Europe and sold four ARTAS 9x Systems in our international markets. Overall, we continue to see increased interest and growing demand for ARTAS technology. We look forward to continuing to drive our targeted commercial strategy even further in 2019.”

The preliminary unaudited revenue results included in this press release are prior to the completion of review and audit procedures by the Company’s independent registered public accounting firm and are therefore subject to adjustment. The Company plans to release its fourth quarter and full year 2018 financial results in early March 2019.

About Restoration Robotics

Restoration Robotics, Inc., is a medical device company developing and commercializing the ARTAS® and ARTAS iX™ Robotic Hair Restoration System. The ARTAS Systems are the first and only physician-assisted robotic systems to dissect and assist in the harvesting of follicular units directly from the scalp, create recipient implant sites using proprietary algorithms and simultaneously implant the hair follicles into the designated sites. The Company has unique expertise in machine vision, image guidance, visual servoing and robotics, as well as developing intuitive interfaces to manage these technologies.

Forward-Looking Statements

Statements made in this press release that are not statements of historical fact are forward-looking statements. Forward-looking statements are subject to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are commonly identified by words such as “would,” “may,” “expects,” “believes,” “plans,” “intends,” “projects” and other terms with similar meaning. Investors are cautioned that the forward-looking statements in this document are based on current beliefs, assumptions and expectations, speak only as of the date of this document and involve risks and uncertainties that could cause actual results to differ materially from current expectations. Such statements, including our expectations for fourth quarter 2018 revenue and the timing of release of our full year 2018 financial results, are subject to certain known and unknown risks and uncertainties, many of which are difficult to predict and generally beyond our control, that could cause actual results and other future events to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. Material factors that could cause actual results to differ materially from current expectations include, without limitation, the following: the progress of our commercialization, marketing and manufacturing capabilities; and the timing or likelihood of regulatory filings and approvals for ARTAS for use in transplanting of hair. These factors, together with those that are described in greater detail in our Annual Report on Form 10-K filed on March 5, 2018, as well as any reports that we may file with the SEC in the future, including our Quarterly Report for the nine months ended September 30, 2018  filed on November 5, 2018, may cause our actual results, performance or achievements to differ materially and adversely from those anticipated or implied by our forward-looking statements. We expressly disclaim any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements. We expressly disclaim any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements. Our preliminary operating results for the quarter and full year ended December 31, 2018 are subject to adjustment as we complete our year-end audit and other processes and are not necessarily indicative of our operating results for any future periods.



Media Contact

Lisa Markle

Director of Marketing

Restoration Robotics, Inc.

4

Investor Contact

The Ruth Group

Brian Johnston



646-536-7000

EN
07/01/2019

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Restoration Robotics Inc

 PRESS RELEASE

Venus Concept Announces Fourth Quarter and Fiscal Year 2019 Financial ...

Venus Concept Announces Fourth Quarter and Fiscal Year 2019 Financial Results; Provides Preliminary First Quarter of 2020 Revenue Results and Updates Fiscal Year 2020 Revenue Guidance TORONTO, March 30, 2020 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced financial results for the three months and twelve months ended December 31, 2019 and preliminary revenue results for the three months ending March 31, 2020. The Company notes that the financial results provided for the three months and twelv...

 PRESS RELEASE

Venus Concept Inc. Announces $22.25 Million Equity Financing

Venus Concept Inc. Announces $22.25 Million Equity Financing TORONTO, March 18, 2020 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced that it entered into a definitive agreement for the sale of shares of its common stock, Series A convertible preferred stock and warrants to purchase common stock in a private placement to a group of investors, including EW Healthcare Partners, HealthQuest Capital and SEDCO Capital. The private placement is expected to result in gross proceeds to the Compa...

 PRESS RELEASE

Venus Concept to Release Fourth Quarter and Fiscal Year 2019 Financial...

Venus Concept to Release Fourth Quarter and Fiscal Year 2019 Financial Results on March 30, 2020 TORONTO, March 10, 2020 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced that fourth quarter and fiscal year 2019 financial results will be released after the market closes on Monday, March 30. Management will host a conference call at 5:00 p.m. Eastern Time on March 30 to discuss the results of the quarter and the year with a question and answer session. Those who would like to participate may di...

 PRESS RELEASE

Venus Concept Expands Executive Team

Venus Concept Expands Executive Team Chad A. Zaring, Appointed Chief Commercial Officer TORONTO, March 03, 2020 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced that it has expanded its Executive Team with the appointment of Chad A. Zaring to the newly-created role of Chief Commercial Officer (“CCO”), effective February 10, 2020. Mr. Zaring has extensive experience in building and executing commercial strategies and driving sales for leading surgical robotics companies in his career. “We ar...

 PRESS RELEASE

Venus Concept Inc. Announces New Regulatory Clearances

Venus Concept Inc. Announces New Regulatory Clearances CE Mark Approval for Venus Bliss™️ for Non-Invasive Lipolysis of Abdomen & Flanks, Skin Tightening, Circumferential Reduction and Cellulite ReductionHealth Canada License to Market NeoGraft 2.0 for hair restoration TORONTO, Feb. 14, 2020 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced that it has received CE Mark approval to market Venus Bliss for non-invasive lipolysis of the abdomen and flanks, skin tightening, circumferential re...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch